Shree Ram Proteins Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Shree Ram Proteins zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Food Gewinnwachstum	16.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Dec 11

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Nov 06

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Jun 19

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Feb 24

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Shree Ram Proteins jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NSEI:SRPL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2024	57	-103	N/A	N/A	N/A
3/31/2024	148	-96	6	6	N/A
12/31/2023	391	-53	N/A	N/A	N/A
9/30/2023	768	-2	27	27	N/A
6/30/2023	1,195	27	N/A	N/A	N/A
3/31/2023	1,627	38	-214	-202	N/A
12/31/2022	2,367	52	N/A	N/A	N/A
9/30/2022	2,688	59	126	139	N/A
6/30/2022	3,012	65	N/A	N/A	N/A
3/31/2022	2,878	61	360	363	N/A
12/31/2021	2,699	79	N/A	N/A	N/A
9/30/2021	2,527	64	54	56	N/A
6/30/2021	1,817	33	N/A	N/A	N/A
3/31/2021	1,526	8	8	9	N/A
12/31/2020	1,468	-11	N/A	N/A	N/A
9/30/2020	1,248	-13	-26	-26	N/A
6/30/2020	1,404	7	14	14	N/A
3/31/2020	1,559	26	54	54	N/A
12/31/2019	1,273	19	N/A	N/A	N/A
9/30/2019	1,429	38	51	51	N/A
6/30/2019	1,505	36	65	68	N/A
3/31/2019	1,581	33	79	85	N/A
12/31/2018	1,853	26	-1	8	N/A
9/30/2018	2,127	19	-83	-70	N/A
6/30/2018	2,040	19	-113	-104	N/A
3/31/2018	1,954	18	N/A	-137	N/A
3/31/2017	1,574	6	N/A	72	N/A
3/31/2016	1,833	5	N/A	12	N/A
3/31/2015	1,744	14	N/A	94	N/A
3/31/2014	1,573	13	N/A	-130	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SRPL über der Sparquote liegt (6.7%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SRPL schneller wachsen werden als der Markt Indian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SRPL in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SRPL schneller wachsen werden als der Markt von Indian.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SRPL schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SRPL in 3 Jahren voraussichtlich hoch sein wird

Shree Ram Proteins Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

First quarter 2025 earnings released: ₹0.02 loss per share (vs ₹0.01 profit in 1Q 2024)

Full year 2024 earnings released: ₹0.45 loss per share (vs ₹0.18 profit in FY 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Now 22% overvalued after recent price rise

Now 24% overvalued after recent price rise

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.048 profit in 2Q 2023)

Shree Ram Proteins Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Less than half of directors are independent

Full year 2023 earnings released: EPS: ₹0.18 (vs ₹0.29 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: ₹1.79 (vs ₹2.87 in FY 2022)

Investor sentiment improves as stock rises 16%

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorates as stock falls 17%

Chairman & MD recently sold ₹4.9m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.25 (vs ₹0.56 in 3Q 2022)

Chairman & MD recently sold ₹2.0m worth of stock

Investor sentiment deteriorated over the past week

Non Executive Director recently sold ₹7.3m worth of stock

Non Executive Director recently bought ₹40m worth of stock

Insider recently sold ₹2.4m worth of stock

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹1.7m worth of stock

Chairman & MD recently bought ₹2.4m worth of stock

Second quarter 2023 earnings released: EPS: ₹0.48 (vs ₹0.77 in 2Q 2022)

Less than half of directors are independent

Chairman & MD recently bought ₹1.6m worth of stock

Investor sentiment deteriorated over the past week

Promoter & Whole-Time Director recently sold ₹10m worth of stock

Promoter & Whole-Time Director recently sold ₹3.2m worth of stock

Promoter & Whole-Time Director recently sold ₹2.8m worth of stock

Investor sentiment deteriorated over the past week

Shree Ram Proteins Limited, Annual General Meeting, Jul 18, 2022

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Promoter & Whole-Time Director recently sold ₹11m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Chairman & MD recently sold ₹4.5m worth of stock

Investor sentiment deteriorated over the past week

Chairman & MD recently sold ₹2.8m worth of stock

Full year 2022 earnings released: EPS: ₹2.87 (vs ₹0.39 in FY 2021)

Chairman & MD recently sold ₹3.7m worth of stock

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Investor sentiment improved over the past week

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS ₹0.77 (vs ₹1.27 loss in 2Q 2021)

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Full year 2021 earnings released: EPS ₹0.39 (vs ₹1.22 in FY 2020)

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: ₹0.16 loss per share (vs ₹0.22 loss in 3Q 2020)

New 90-day high: ₹37.35

Shree Ram Proteins Limited Announces Board Changes

New 90-day low: ₹29.55

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken